

GODIF Newsletter December to February 2026

Thank you for committing to the GODIF trial!

Dear friends and colleagues,

Recruitment

In 2025, 162 participants were enrolled in the GODIF trial. We would like to thank you all for your contributions and congratulate the top recruiters in 2025. The ICU at Rigshospitalet (DK) was the top recruiter in 2025 with 29 participants. The ICU in Bern (CH) and the ICU in Groningen (NL) were the monthly top recruiters with 5 randomisations within one month. The best weekly recruiters were the ICU in Bern (CH), the ICU in Odense and Aalborg (DK), with 3 randomisations within one week. Well done!



We have now reached a total of 805 participants out of 1000. The trial is active in Switzerland, the Netherlands, Australia, Lithuania, the Czech Republic, and Denmark. The trial is planned to finish enrolment before 31.12.2026. For that to succeed, we need 5 enrolments per week. We need your

help to reach the goal so we can finalise the study with the planned sample size. Please keep up your good work. Let us know if we can assist you in any way.

News

Lithuania has randomised their first three participants – congratulations! IKEM in Praha in the Czech Republic will start the trial at the end of February. Two more sites in the Czech Republic, Ostrava and Pilsen, respectively, are expected to start soon. We are looking forward to the collaboration.

Trial drug

The trial drug at the Dutch and Danish sites will expire on 28.06.2026. A production of fresh medicine is being prepared and will be distributed to all relevant sites at the beginning of June.



Annual safety report

The annual safety report has been submitted to EMA in the clinical trials information system on the 3rd of February and is still under evaluation. We will send you the report as soon as it is approved by the authorities.

New documents for your site master file.

- For Danish sites. The trial information for the trial guardian in Word format has been updated with the correct year in the header.
- A new co-enrolment list version 1.8
- New documents will always be attached to the newsletter sent out four

The Coordinating Centre is always available on the
GODIF hotline: +45 48 29 67 73

Mail: godif@cric.nu

www.cric.nu/godif/

Kind Regards from the GODIF team

Morten (Sponsor) and Sine (Coordinating Investigator)



Thank you for your continued commitment to the GODIF trial. We truly appreciate your dedication and hard work.

**All the best,
Morten and Sine**

